We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About ENYO Pharma Stock

Invest in or calculate the value of your shares in ENYO Pharma or other pre-IPO companies through EquityZen's platform.

Get Started

ENYO Pharma Stock (ENPH)

ENYO Pharma is a biopharmaceutical company based in Lyon, France.

About ENYO Pharma Stock

Founded

2014

Industries

Software, Artificial Intelligence, Data and Analytics

ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). The company is based in the Infectiology Center of LyonbiopĂ´le in Lyon, France and maintains tight collaborations with the seminal Inserm team and the BSL4 laboratory Inserm-Jean MĂ©rieux. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules. The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.

ENYO Pharma Press Mentions

Stay in the know about the latest news on ENYO Pharma

ENYO Pharma Management

Leadership team at ENYO Pharma

Founder, President and CEO

Jacky Vonderscher

Co-Founder and Head of Drug Discovery Platform

Benoit Chassey

Locked Features

Join now and verify your accreditation status to gain access to:

  • ENYO Pharma current valuation
  • ENYO Pharma stock price
  • Available deals in ENYO Pharma and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading ENYO Pharma Stock

How to invest in ENYO Pharma stock?

Accredited investors can buy pre-IPO stock in companies like ENYO Pharma through EquityZen funds. These investments are made available by existing ENYO Pharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell ENYO Pharma stock?

Shareholders can sell their ENYO Pharma stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."